Abstract: The present invention relates to ultrasound mediated delivery of therapeutic agents to the central nervous system (CNS). Thus, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of therapeutic agents to the brain and spinal cord for treatment. The invention further provides compositions and methods to increase permeability of the blood-brain barrier for passage of therapeutic agents to allow for medical treatment of diseases, disorders and injuries of the CNS.

Abstract: Disclosed herein are ultrasound methods utilizing various frequencies and other parameters to enhance immunotherapeutic treatments. The disclosure further provides various settings and timing for the ultrasound pulses to be delivered to a targeted region of tissue in the body.

Abstract: The present invention relates to ultrasound mediated delivery of therapeutic agents to the central nervous system (CNS). Thus, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of therapeutic agents to the brain and spinal cord for treatment. The invention further provides compositions and methods to increase permeability of the blood-brain barrier for passage of therapeutic agents to allow for medical treatment of diseases, disorders and injuries of the CNS.

Abstract: The present invention relates to ultrasound mediated enhancement of immunotherapeutic medicinal agents and regimens, and particularly for immunotherapeutic treatment of cancers and autoimmune diseases. More particularly, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of immunotherapeutic agents to a targeted region of interest in the body and in enhancement of activated immune cell infiltration to targeted pathological conditions, and for treatment of solid tumours and autoimmune pathologies.

Abstract: The present disclosure related to a method of using high frequency sound waves directed toward an acoustically active particle. The high frequency sound waves may be configured to enlarge the acoustically active particle and oscillate the acoustically active particle, thereby facilitating extravasation of an agent to a tissue compartment of a region of interest.

Abstract: Disclosed herein are methods relating to manufacturing an embolizing agent precursor. Manufacture of the embolizing agent precursor may involve mixing a first component contained within a first container with a second component contained within a second container, the first component including a plurality of negatively charged gaseous components and a first stabilizer, the second component comprising a plurality of positively charged oil components, a second stabilizer, and a cationic surfactant. Further steps may include mixing the first component with the second component such that the first and second component are held together as a single agglomerated entity.

Abstract: The present disclosure relates to a method of imaging, involving administration of a bi-phasic formulation followed by application of high frequency sound waves to identify a region of interest. Following identification, a phase shift of the bi-phasic formulation may be activated by a second administration of high frequency sound waves such that gaseous components of the bi-phasic formulation are enlarged and localised at the region of interest.

Abstract: Disclosed herein are compositions and methods for an embolizing agent precursor. The embolizing agent precursor may include a gaseous component and a first stabilizer to stabilize the gaseous component, the first stabilizer may include a a polymer, and wherein a gas portion of the gaseous component is selected from the group consisting of sulphur hexafluoride and C3-6 perfluorocarbons. The embolizing agent precursor may further include an oil component which comprises a C1-7 hydrocarbon, a second stabilizer to stabilize the oil component, and a vaporous component configured to enlarge the gaseous component.

Abstract: The present invention relates to ultrasound mediated delivery of antimicrobial agents to sites of infection, and particularly for treatment of infections. Thus, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery and preparation for administration of antimicrobial agents and treatment of infections.

Abstract: The present invention relates to ultrasound mediated delivery of therapeutic agents to the pancreas, and particularly for treatment of pancreatic cancer such as pancreatic ductal adenocarcinoma (PDAC). More particularly, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of therapeutic agents and for treatment of pancreatic cancers, including PDAC.

Abstract: The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

Abstract: Disclosed is an ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system including gas microbubbles, emulsion microdroplets and clusters thereof. Also, disclosed are a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. Moreover, disclosed are a method for delivering such therapeutic agents and the use of said compositions.

Abstract: A method is provided including obtaining ultrasound information including anatomy information representative of a portion of anatomy to be imaged and artifact information representative of a coherent interference artifact. A contrast agent has been associated with the coherent interference artifact. Due to association with the contrast agent, the coherent interference artifact appears in different realizations in a plurality of readings taking along a single line. The method also includes suppressing the artifact information to form revised ultrasound information. Suppressing the artifact information includes using the plurality of readings to suppress the artifact information. Also, the method includes reconstructing the ultrasound image using the revised ultrasound information.

Abstract: The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with a benzopyrylium dye suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC).

Abstract: The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods.

Abstract: The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with a benzopyrylium dye suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC).